regulatory-trust-commitment

Regulatory & Trust Commitment

Swiss Vitalis USA is committed to responsible cannabinoid product manufacturing, labeling, and transparency.

Core compliance statement:

  • All Swiss Vitalis USA hemp-derived products are independently tested and contain ≤ 0.3% Δ-9 THC on a dry-weight basis.
  • Every batch is supported by a batch-specific Certificate of Analysis (COA).
  • We provide mg-per-dose transparency and clear risk warnings to support informed decisions.

1) Regulatory compliance commitments

  • U.S. hemp compliance (Farm Bill): Our hemp-derived products are formulated and labeled to comply with U.S. federal hemp definitions, including ≤ 0.3% Δ-9 THC (dry weight), as demonstrated in independent, third-party testing.
  • No scattered disclosures: Our compliance statements and testing commitments are centralized on this page to support consistent, verifiable communication.
  • Brazil (ANVISA) documentation support: For customers and partners in Brazil, we support documentation commonly requested for patient import pathways under ANVISA RDC 660/2022 (where applicable), including COAs, ingredient lists, and product specifications. We do not claim that products are “approved” or “registered” by ANVISA unless explicitly stated for a specific item in writing.

2) Independent testing standards

  • ISO-accredited labs: We prioritize testing performed by independent laboratories accredited to ISO/IEC 17025 (or equivalent).
  • Batch-specific COAs: COAs are intended to match the batch/lot of the product you receive and may include:
  • Cannabinoid profile (including Δ-9 THC)
  • Heavy metals
  • Pesticides
  • Microbials
  • Residual solvents
  • Mycotoxins (when applicable)

Transparency over marketing: If a test panel is not shown on a COA for a given batch, we do not imply it was performed.

How to read COAs (Guide)

3) GMP & responsible manufacturing

  • GMP approach: We work with manufacturing partners that follow Good Manufacturing Practices (GMP) and quality systems appropriate for cannabinoid products, such as lot traceability, SOPs, controlled production/packaging processes, and label review/change control.
  • Quality is a process: Quality controls are built into sourcing, production, and release—not added after the fact.

4) mg-per-dose transparency

  • Clear labeling: Product pages and labels provide mg-per-serving / mg-per-dose whenever applicable.
  • COAs support transparency: Batch testing supports cannabinoid disclosure and helps customers verify what’s in the product.

5) Safety, risk warnings, and responsible use

  • Not intended to diagnose, treat, cure, or prevent any disease.
  • Keep out of reach of children and pets.
  • Adults only.
  • Pregnancy/nursing: Do not use if pregnant or nursing unless directed by a licensed healthcare professional.
  • Drug interactions: Consult a healthcare professional before use if you take prescription medications or have a medical condition.
  • Impairment risk: Do not drive or operate machinery after use if you feel drowsy or impaired.
  • Drug testing warning: Even hemp-derived products may contain trace cannabinoids. Use may trigger a positive drug test.
  • Allergen/ingredient review: Always review the ingredient list before use.

6) FAQs

Do your products contain ≤ 0.3% Δ-9 THC?

Yes. All Swiss Vitalis USA hemp-derived products are independently tested and contain ≤ 0.3% Δ-9 THC on a dry-weight basis, as shown on batch-specific COAs.

Where can I learn how to interpret a COA?

Use our COA guide: https://www.swissvitalisusa.com/pages/understanding-coas-essential-guide-for-consumers

Where are your FAQs/Answers?

Our FAQs are here: https://www.swissvitalisusa.com/pages/answers

Can these products make me fail a drug test?

Possibly. Even compliant hemp-derived products may contain trace cannabinoids. Use may trigger a positive drug test.

For more, visit: FAQs (Answers)